AZGP1P2 overexpression enhances the sensitivity of castration-resistant prostate cancer cells to docetaxel, reduces migration, increases apoptosis, and reduces prostate CSC markers, including KLF4 and SOX2, in castration-resistant prostate cancer cells. This evidence concerns the gene AZGP1P2 and prostate carcinoma.